Mereo BioPharma Group PLC (LON:MPH) Insider Buys £5,100 in Stock

Mereo BioPharma Group PLC (LON:MPH) insider Denise Scots-Knight purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The shares were purchased at an average cost of GBX 51 ($0.67) per share, for a total transaction of £5,100 ($6,664.05).

Mereo BioPharma Group stock opened at GBX 41 ($0.54) on Monday. Mereo BioPharma Group PLC has a 12-month low of GBX 40 ($0.52) and a 12-month high of GBX 320 ($4.18). The stock has a market cap of $40.16 million and a P/E ratio of -0.91. The company has a debt-to-equity ratio of 65.56, a current ratio of 2.13 and a quick ratio of 2.05. The business’s fifty day moving average price is GBX 56.28.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Recommended Story: What is the Dividend Aristocrat Index?

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with's FREE daily email newsletter.